Literature DB >> 25972152

Role of Dopamine and D2 Dopamine Receptor in the Pathogenesis of Inflammatory Bowel Disease.

Ganna Tolstanova1,2, Xiaoming Deng3, Amrita Ahluwalia3, Brankica Paunovic3, Alona Prysiazhniuk4, Lyudmyla Ostapchenko4, Andrzej Tarnawski3, Zsuzsanna Sandor3, Sandor Szabo5.   

Abstract

BACKGROUND: VEGF-induced vascular permeability and blood vessels remodeling are key features of inflammatory bowel disease (IBD) pathogenesis. Dopamine through D2 receptor (D2R) inhibits VEGF/VPF-mediated vascular permeability and angiogenesis in tumor models. In this study, we tested the hypothesis that pathogenesis of IBD is characterized by the disturbance of dopaminergic system and D2R activity.
METHODS: IL-10 knockout (KO) mice and rats with iodoacetamide-induced ulcerative colitis (UC) were treated intragastrically with D2R agonists quinpirole (1 mg/100 g) or cabergoline (1 or 5 µg/100 g). Macroscopic, histologic, and clinical features of IBD, colonic vascular permeability, and angiogenesis were examined.
RESULTS: Although colonic D2R protein increased, levels of tyrosine hydroxylase and dopamine transporter DAT decreased in both models of IBD. Treatment with quinpirole decreased the size of colonic lesions in rats with iodoacetamide-induced UC (p < 0.01) and reduced colon wet weight in IL-10 KO mice (p < 0.05). Quinpirole decreased colonic vascular permeability (p < 0.001) via downregulation of c-Src and Akt phosphorylation. Cabergoline (5 µg/100 g) reduced vascular permeability but did not affect angiogenesis and improved signs of iodoacetamide-induced UC in rats (p < 0.05).
CONCLUSIONS: Treatment with D2R agonists decreased the severity of UC in two animal models, in part, by attenuation of enhanced vascular permeability and prevention of excessive vascular leakage. Hence, the impairment dopaminergic system seems to be a feature of IBD pathogenesis.

Entities:  

Keywords:  Animal models; D2 dopamine receptor; Dopamine; Inflammatory bowel disease; Vascular permeability

Mesh:

Substances:

Year:  2015        PMID: 25972152     DOI: 10.1007/s10620-015-3698-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  65 in total

1.  Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study.

Authors:  F McKenna; P J McLaughlin; B J Lewis; G C Sibbring; J A Cummerson; D Bowen-Jones; R J Moots
Journal:  J Neuroimmunol       Date:  2002-11       Impact factor: 3.478

2.  Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both.

Authors:  Michal J Besser; Yonatan Ganor; Mia Levite
Journal:  J Neuroimmunol       Date:  2005-09-15       Impact factor: 3.478

3.  Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment.

Authors:  F Magro; E Cunha; F Araujo; E Meireles; P Pereira; M Dinis-Ribeiro; F Tavarela Veloso; R Medeiros; P Soares-da-Silva
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

4.  The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.

Authors:  S Basu; J A Nagy; S Pal; E Vasile; I A Eckelhoefer; V S Bliss; E J Manseau; P S Dasgupta; H F Dvorak; D Mukhopadhyay
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

5.  Differential effect of changing central and peripheral catecholamine levels in cysteamine-induced duodenal ulcer in the rat.

Authors:  H C Horner; S Szabo
Journal:  Life Sci       Date:  1981-12-07       Impact factor: 5.037

6.  DOPA, dopamine, and DOPAC concentrations in the rat gastrointestinal tract decrease during fasting.

Authors:  E Eldrup; E A Richter
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-10       Impact factor: 4.310

7.  Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction.

Authors:  Claudio Alvarez; Luis Martí-Bonmatí; Edurne Novella-Maestre; Roberto Sanz; Raúl Gómez; Manuel Fernández-Sánchez; Carlos Simón; Antonio Pellicer
Journal:  J Clin Endocrinol Metab       Date:  2007-04-24       Impact factor: 5.958

8.  Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice.

Authors:  Zhi Shan Li; Claudia Schmauss; Abigail Cuenca; Elyanne Ratcliffe; Michael D Gershon
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

9.  Neutralizing anti-vascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF.

Authors:  Ganna Tolstanova; Tetyana Khomenko; Xiaoming Deng; Longchuan Chen; Andrzej Tarnawski; Amrita Ahluwalia; Sandor Szabo; Zsuzsanna Sandor
Journal:  J Pharmacol Exp Ther       Date:  2008-12-05       Impact factor: 4.030

10.  Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease.

Authors:  Christopher B Forsyth; Kathleen M Shannon; Jeffrey H Kordower; Robin M Voigt; Maliha Shaikh; Jean A Jaglin; Jacob D Estes; Hemraj B Dodiya; Ali Keshavarzian
Journal:  PLoS One       Date:  2011-12-01       Impact factor: 3.240

View more
  15 in total

Review 1.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

2.  Source of dopamine in gastric juice and luminal dopamine-induced duodenal bicarbonate secretion via apical dopamine D2 receptors.

Authors:  Xiao-Yan Feng; Jing-Ting Yan; Guang-Wen Li; Jing-Hua Liu; Rui-Fang Fan; Shi-Chao Li; Li-Fei Zheng; Yue Zhang; Jin-Xia Zhu
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 3.  Neuroprotective strategies for retinal disease.

Authors:  Machelle T Pardue; Rachael S Allen
Journal:  Prog Retin Eye Res       Date:  2018-02-23       Impact factor: 21.198

4.  Activation of Dopamine D1 Receptors in Dermal Fibroblasts Restores Vascular Endothelial Growth Factor-A Production by These Cells and Subsequent Angiogenesis in Diabetic Cutaneous Wound Tissues.

Authors:  Debanjan Chakroborty; Chandrani Sarkar; Kai Lu; Madhavi Bhat; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Am J Pathol       Date:  2016-07-13       Impact factor: 4.307

Review 5.  Targeting the Dopaminergic System in Autoimmunity.

Authors:  Pia M Vidal; Rodrigo Pacheco
Journal:  J Neuroimmune Pharmacol       Date:  2019-01-19       Impact factor: 4.147

Review 6.  Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis.

Authors:  Rahul Mittal; Luca H Debs; Amit P Patel; Desiree Nguyen; Kunal Patel; Gregory O'Connor; M'hamed Grati; Jeenu Mittal; Denise Yan; Adrien A Eshraghi; Sapna K Deo; Sylvia Daunert; Xue Zhong Liu
Journal:  J Cell Physiol       Date:  2017-04-10       Impact factor: 6.384

7.  α-Synuclein disrupts the anti-inflammatory role of Drd2 via interfering β-arrestin2-TAB1 interaction in astrocytes.

Authors:  Ren-Hong Du; Yan Zhou; Mei-Ling Xia; Ming Lu; Jian-Hua Ding; Gang Hu
Journal:  J Neuroinflammation       Date:  2018-09-10       Impact factor: 8.322

8.  The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice.

Authors:  Meghan May; Megan Beauchemin; Calvin Vary; Deborah Barlow; Karen L Houseknecht
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

9.  Trioxolone Methyl, a Novel Cyano Enone-Bearing 18βH-Glycyrrhetinic Acid Derivative, Ameliorates Dextran Sulphate Sodium-Induced Colitis in Mice.

Authors:  Andrey V Markov; Aleksandra V Sen'kova; Oksana V Salomatina; Evgeniya B Logashenko; Dina V Korchagina; Nariman F Salakhutdinov; Marina A Zenkova
Journal:  Molecules       Date:  2020-05-21       Impact factor: 4.411

10.  A colon-specific prodrug of metoclopramide ameliorates colitis in an experimental rat model.

Authors:  Yejin Yang; Wooseong Kim; Dayoon Kim; Seongkeun Jeong; Jin-Wook Yoo; Yunjin Jung
Journal:  Drug Des Devel Ther       Date:  2018-12-28       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.